Clinical trials
Small Cell Carcinoma clinical trials
Below are recruiting small cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 782 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07509034RecruitingPhase 1
Targeted immune cells for recurrent small cell lung cancer
This trial tests a special immune cell therapy (CAR T cells) that targets a protein called B7-H3 on your cancer cells. It is for people with small cell lung cancer or similar neuroendocrine cancers that have returned or not responded to standard treatments.
Bethesda, MarylandAges 18–120 - NCT07288034RecruitingPhase 2
Immunotherapy biomarkers for advanced lung cancer
This study looks at blood and tissue biomarkers to predict how well immunotherapy (with or without chemotherapy) works for advanced non-small cell lung cancer. It also helps decide the best second treatment if the first one stops working.
Goodyear, ArizonaAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial tests an experimental drug called NKT3964 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Little Rock, ArkansasAges 19 years+ - NCT06623422RecruitingPhase 3
Vaccine plus Keytruda for lung cancer after surgery
This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.
Gilbert, ArizonaAges 18 years+ - NCT07388524RecruitingPhase 3
Testing atezolizumab after surgery for early stage lung cancer
This trial tests if the immunotherapy drug atezolizumab can prevent early stage non-small cell lung cancer from coming back after surgery. It is for people whose tumors have high levels of a protein called PD-L1 (50% or more) and do not have certain gene changes (EGFR or ALK).
Beverly Hills, CaliforniaAges 18 years+ - NCT05037825Recruiting
Study gut microbes with immune therapy in several solid cancers
This trial looks at how the gut microbiome (the bacteria in your digestive system) relates to outcomes when you take standard immune “checkpoint” cancer medicines. If you’re eligible, they’ll collect stool samples while you receive treatment for certain cancers.
Elizabethtown, KentuckyAges 18 years+ - NCT06192849RecruitingPhase 2
Furmonertinib after surgery for EGFR 20 insertion lung cancer
This trial tests a targeted pill (furmonertinib) to prevent your lung cancer from coming back after surgery. It is for people with a certain genetic change in their tumor (EGFR exon 20 insertion) and stage IB, II, or IIIA disease.
Chengdu, SichuanAges 18 years+ - NCT06247605RecruitingPhase 3
Study of AL8326 for advanced small cell lung cancer
This trial tests a new oral drug called AL8326 for people with advanced small cell lung cancer who have already tried at least two other treatments. The goal is to see if the drug can shrink tumors and help patients live longer.
Changchun, JilinAges 18 years+ - NCT06255197Recruiting
Study of lung cancer surgery patients and their outcomes
This study looks at the characteristics, treatments, and results of people who have had surgery to remove lung cancer. It aims to help doctors understand what happens after surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07855965RecruitingPhase 2
Ablation with immunotherapy and chemo before lung cancer surgery
This study tests a new approach for people with early-stage lung cancer that can be removed with surgery. Before surgery, patients receive a treatment called cryo-thermal ablation to freeze and heat the tumor, along with an immunotherapy drug (toripalimab) and chemotherapy. The goal is to see if this combination shrinks tumors and improves outcomes after surgery.
Chengdu, SichuanAges 18–80 - NCT06053099Recruiting
Study of osimertinib after surgery for EGFR-mutated lung cancer
This trial collects data from people with early-stage lung cancer that has a common EGFR mutation. After complete surgical removal of the tumor, participants take osimertinib for 3 years and are followed regularly to see how well the treatment works and why resistance might develop.
AngersAges 18 years+ - NCT05098119RecruitingPhase 2
Study drugs before surgery for mouth or throat cancer
This Phase 2 trial tests giving the immunotherapy drug sintilimab before surgery, along with fewer chemotherapy cycles. The goal is to shrink or control oral or throat squamous cell cancers while keeping side effects lower, before the tumor is removed.
Guangzhou, GuangdongAges 18–80 - NCT07843940RecruitingPhase 1/Phase 2
Two study drugs for extensive-stage small cell lung cancer
This trial tests two new immunotherapy drugs (obrixtamig and pumitamig) given together for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and helps shrink or control the cancer.
Miami, FloridaAges 18 years+ - NCT06464068RecruitingPhase 2
Immunotherapy plus chemo for first-line advanced extrapulmonary small cell cancer
This trial tests a new combination of durvalumab (an immunotherapy) plus standard chemotherapy for people with advanced small cell carcinoma that started outside the lung and has not been treated before. The goal is to see if this combo works better than chemo alone.
Reggio EmiliaAges 18 years+ - NCT07784959RecruitingPhase 1
Study of NXP900 with lorlatinib for ALK-positive lung cancer
This study tests a new drug called NXP900 in combination with lorlatinib for people with ALK-positive lung cancer who have already been treated with lorlatinib and tolerated it well. The goal is to see if this combination is safe and effective.
Fairfax, VirginiaAges Any age - NCT07783477RecruitingPhase 1
Armored CAR T cells for DLL3 positive cancers
This trial tests an experimental treatment using your own immune cells, modified to better find and attack cancer cells that carry a marker called DLL3. It is for people with certain neuroendocrine tumors, including small cell lung cancer, who have already tried standard treatments.
Basking Ridge, New JerseyAges 18 years+ - NCT07776353Recruiting
Understanding weight loss in advanced cancer
This study looks at how weight loss and muscle loss affect people with advanced cancer. It aims to find different types of weight loss to better guide treatment and care.
Pleasanton, CaliforniaAges 18 years+ - NCT02511288Recruiting
Blood tests to monitor advanced lung cancer during care
This study checks whether “liquid biopsies” (blood tests) can help monitor advanced non-small-cell lung cancer. It looks at different patient groups based on timing and tumor features, aiming to make cancer tracking easier and less invasive.
AnnecyAges 18 years+ - NCT05014464RecruitingPhase 2
Testing ALK-targeted pills for ALK-positive advanced squamous cancer
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
Changsha, HunanAges 18 years+ - NCT06247163Recruiting
PET-guided radiation for small cell lung cancer
This trial uses PET scans to guide radiotherapy for people with limited-stage small cell lung cancer, aiming to improve treatment accuracy. It is designed for those whose cancer has not spread extensively.
EssenAges 18 years+ - NCT06623487Recruiting
PET scan to guide immunotherapy for stage III lung cancer
This trial uses a special scan (68Ga-grazytracer PET) to see how well immunotherapy works for stage III non-small cell lung cancer before surgery or radiation. It aims to help doctors choose the best treatment for you.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07718672RecruitingPhase 2
New radiation technique for early-stage lung cancer
This trial compares a newer, more targeted type of radiation (hotspot SABR) with the standard SABR approach for people with early-stage non-small cell lung cancer. The goal is to see if the newer method works just as well or better while possibly reducing side effects.
Buffalo, New YorkAges 18 years+ - NCT05487391RecruitingPhase 3
QL1706 plus chemo after lung cancer surgery
This trial studies whether a study drug called QL1706 added to standard platinum chemotherapy can lower the chance of lung cancer coming back after surgery. It targets people with stage II to IIIB non-small cell lung cancer who have had their tumor fully removed.
ShanghaiAges 18 years+ - NCT07668037Recruiting
Understanding long-term survival in NSCLC immunotherapy
This study looks at patients with advanced non-small cell lung cancer who received immunotherapy (immune checkpoint inhibitors) alone or in combination with other treatments. It aims to understand why some patients survive longer than others by analyzing their medical data and using AI to predict outcomes.
BeijingAges 18 years+
Hear when a new Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for small cell carcinoma?
- Yes. Clin2 currently lists 782 recruiting small cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a small cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a small cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.